Episode 87 - Flitting About | In The Lab: FLT3 and NPM1

“It’s pronounced nuc-ul-ophosmin” “Nucleophosmin”. “Noo-clee-o-phosmin”. FLT3-ITD got you In The Dumps? Have a Total Knowledge Deficit about TKD mutations? Struggling with the A-B-Cs of NPM1 mutations? Want to know how a cat sarcoma is somehow related to AML? Join the Bloody Minded Crew as they flit about the laboratory looking at the structure of FLT3 and NPM1, what these proteins usually do and how we test for mutations in the advanced myeloid episode.== Edit 6/5/26 = We've been made aware that strictly speaking the current MANE approved transcript for NPM1.1 has only 11 exons and therefore the mutations are best to be considered in Exon 11 as opposed to exon 12 - in contrast to what we said. ==Timestamps0:52 - Bloody Minded issues a formal apology2:40 - Introducing molecular chaperones5:05 - What even NPM1?9:30 - Functions of NPM110:55 - Molecular biology of NPM1 in disease15:42 - Why the subtypes are important19:53 - NPM1 prognosis21:35 - MRD testing in NPM125:52 - NPM1 summary27:13 - Intro to FLT328:30 - Mandatory FLT3 history36:28 - FLT3 pathogenesis37:37 - FLT3 structure, ITD vs TKD41:16 - The juxtamembrane domain42:53 - Prognostic features in FLT344:17 - TKD mutations46:26 - FLT3 in the lab50:30 - Take home messagesSupport the showCheck out show notes, additional references and (sometimes) extra content at www.bloodyminded.com.au